YESTAR HEALTH (02393) Reports Interim Results with Profit Attributable to Owners of HK$5.761 Million, Down 99.47% YoY

Stock News

Aug 29, 2025

YESTAR HEALTH (02393) announced its interim results for 2025, reporting revenue from continuing operations of approximately HK$803 million, representing a year-on-year decrease of 36.99%. Profit attributable to owners of the company was HK$5.761 million, down 99.47% compared to the same period last year. Earnings per share stood at 0.25 cents. The announcement indicated that the simultaneous decline in revenue and gross profit margin was primarily due to the impact of China's centralized procurement policy on the medical division, which serves as the group's main source of income.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1101906794"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101906794\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101906794?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101906794","market":"hk","top_or_hot":-1,"title":"YESTAR HEALTH (02393) Reports Interim Results with Profit Attributable to Owners of HK$5.761 Million, Down 99.47% YoY","media":"Stock News","content":"<p>YESTAR HEALTH (02393) announced its interim results for 2025, reporting revenue from continuing operations of approximately HK$803 million, representing a year-on-year decrease of 36.99%. Profit attributable to owners of the company was HK$5.761 million, down 99.47% compared to the same period last year. Earnings per share stood at 0.25 cents. The announcement indicated that the simultaneous decline in revenue and gross profit margin was primarily due to the impact of China's centralized procurement policy on the medical division, which serves as the group's main source of income.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>YESTAR HEALTH (02393) Reports Interim Results with Profit Attributable to Owners of HK$5.761 Million, Down 99.47% YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYESTAR HEALTH (02393) Reports Interim Results with Profit Attributable to Owners of HK$5.761 Million, Down 99.47% YoY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-29 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>YESTAR HEALTH (02393) announced its interim results for 2025, reporting revenue from continuing operations of approximately HK$803 million, representing a year-on-year decrease of 36.99%. Profit attributable to owners of the company was HK$5.761 million, down 99.47% compared to the same period last year. Earnings per share stood at 0.25 cents. The announcement indicated that the simultaneous decline in revenue and gross profit margin was primarily due to the impact of China's centralized procurement policy on the medical division, which serves as the group's main source of income.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02393","symbol_name":"巨星医疗控股","start_time":0,"source_url":"","article_id":"1101906794","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101906794","pubTimestamp":1756474233,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"YESTAR HEALTH (02393) announced its interim results for 2025, reporting revenue from continuing operations of approximately HK$803 million, representing a year-on-year decrease of 36.99%. Profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02393":"巨星医疗控股","BK1222":"医疗保健用品"},"translate_title":"巨星健康(02393)公布中期业绩拥有人应占溢利576.1万港元同比下跌99.47%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02393":1},"content_text":"YESTAR HEALTH (02393) announced its interim results for 2025, reporting revenue from continuing operations of approximately HK$803 million, representing a year-on-year decrease of 36.99%. Profit attributable to owners of the company was HK$5.761 million, down 99.47% compared to the same period last year. Earnings per share stood at 0.25 cents. The announcement indicated that the simultaneous decline in revenue and gross profit margin was primarily due to the impact of China's centralized procurement policy on the medical division, which serves as the group's main source of income.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}